University of Southern California
1,017
124
189
516
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
18.9%
192 terminated/withdrawn out of 1017 trials
72.9%
-13.7% vs industry average
7%
67 trials in Phase 3/4
34%
175 of 516 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (1017)
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
Role: lead
Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
Role: lead
MAPT Protocol: Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)
Role: lead
Housing Transitions QUERI
Role: collaborator
The Progressive Supranuclear Palsy Clinical Trial Platform
Role: collaborator
Ketamine HCl Prolonged Release Oral Tablets for CRPS
Role: lead
Early Internal Fixation Versus NonOperative Care With Early Rehabilitation for LC1 Fragility Fractures of the Pelvis
Role: lead
Social Media Influences on Engagement and Susceptibility to Non-combustible Tobacco Product Use Among Youth and Young Adults (AYA)
Role: lead
Bempedoic Acid Therapy for Polycystic Kidney Disease
Role: collaborator
Hyperemesis Gravidarum Risk Reduction With Metformin
Role: lead
Tactile Pre-Visit Imagery
Role: lead
E-cigarette Social Media Marketing and Its Perceptions by Youth
Role: lead
CoGENES Randomized Controlled Trial (RCT)
Role: lead
Clinical Study of STI Screening to Prevent Adverse Birth and New-born Outcomes (Philani Ndiphile)
Role: collaborator
Multi-Site Trial of Tirzepatide for Smoking Cessation
Role: lead
Nutrition for Precision Health, Powered by the All of Us
Role: collaborator
Brain/Craving Response to Smoking Cues After Oral Nicotine Pouch Use
Role: lead
Abuse Liability and Appeal of Oral Nicotine Products
Role: lead
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
Role: lead
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
Role: collaborator